Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | The efficacy of galcanezumab in migraine prevention and impact on premonitory symptoms and triggers

Sait Ashina, MD, Harvard Medical School, Boston, MA, explores the results of two separate but related studies focusing on the role of galcanezumab in preventing migraines and the impact of this medication on migraine prodromes and triggers. The first study underscored the potential of non-allodynia as a predictive indicator for galcanezumab response with considerable accuracy. The second study delved into how galcanezumab influenced the incidence of headache following the occurrence of triggers, premonitory symptoms, or aura, with findings suggesting that the medication significantly reduced these occurrences in those patients where migraines were effectively controlled. Implications of these findings for future treatment strategies and an exploration of genetic components were also discussed. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Ashina has received consulting, teaching, and honoraria from Allergan/AbbVie, Eli Lilly and Company, Impel NeuroPharma, Linpharma, Lundbeck, Satsuma, Percept, Teva and Theranica.